Emilio Cordova, PhD, MBA
Chief Executive Officer

Emilio joined the SAMDI Tech team from AIT Bioscience, where he was the Senior Vice President of Business Development. He has also held executive positions in sales, marketing, and business development at Worldwide Clinical Trials (WCT) and Bioanalytical Systems, Inc (BASi). He brings over 15 years experience in business development, marketing, and sales in contract research companies. Emilio has a PhD in Chemistry from University of Miami, postdoctoral experience at Harvard, and a MBA from Purdue University.

Christian Hodneland, Ph.D., MBA
Managing Director and Co-Head of Pharma/Biotech
Investment Banking
William Blair & Company, LLC

Christian Hodneland, Ph.D., joined William Blair & Company in 2006 and is a Managing Director within the healthcare investment banking group, focused on the pharmaceutical, biotechnology and life science tools sectors. Dr. Hodneland has completed over 50 M&A and financing transactions in his career at William Blair. Prior to joining William Blair, Dr. Hodneland was a Consultant to WMR Biomedical, Inc., a medical device startup developing ophthalmic and cardiovascular products. He also spent three years as a Senior Research Scientist at Surface Logix, Inc., where he managed drug discovery and development programs. Dr. Hodneland received a B.S. in Chemistry from the University of Washington, and a Ph.D. in Chemistry and M.B.A. from the University of Chicago.

Milan Mrksich, Ph.D.
Henry Wade Rogers Professor, Northwestern University

Milan Mrksich joined Northwestern University in 2011, after fifteen years at the University of Chicago. He currently holds faculty appointments in the Departments of Chemistry, Biomedical Engineering and Cell & Molecular Biology. Dr. Mrksich has held advisory positions on the Board of Governors of Argonne National Laboratory, the Department of Defense’s Defense Advanced Research Projects Agency (DARPA), and several academic and editorial boards. He has received many honors, including election as a Fellow of the American Institute for Medical and Biological Engineers, the Arthur Cope Scholar Award, the TR100 Young Innovator Award, and to the list of the top 100 high-impact chemists. He is also a Founder of Arsenal Medical and 480 Biomedical. Dr. Mrksich received a B.S. in Chemistry from the University of Illinois in 1989 and a Ph.D. in Chemistry from the California Institute of Technology in 1994 and then served as an American Cancer Society Postdoctoral Fellow at Harvard University prior to starting his independent career.

Carmichael Roberts, Ph.D., MBA
General Partner, North Bridge Venture Partners

Carmichael Roberts joined North Bridge Venture Partners in 2007 where he is primarily responsible for their investments in chemistry and materials oriented companies. He had previously co-founded and served as the President and Chief Executive Officer of Arsenal Biomedical, Inc., a company that develops implantable medical materials and also of Surface Logix, Inc., an assays and drug optimization company. Carmichael has also co-founded and served as a director of several other ventures, including Ancora Pharmaceuticals, Inc., a carbohydrate materials company and Diagnostics For All, Inc., a non-profit organization that is developing a materials platform to make low cost diagnostics for the poor. Prior to his entrepreneurial career, Carmichael worked in business development at GelTex Pharmaceuticals, Inc., which was acquired by Genzyme for $1.3 billion. Carmichael received his B.S. and Ph.D. in organic chemistry from Duke University and completed his National Science Foundation fellowship at Harvard University. Carmichael also received his M.B.A. from the MIT Sloan School of Management.